Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01230112 · ClinicalTrials.gov registry record

The Role of ITGAM in Systemic Lupus Erythematosus

A clinical trial of Systemic Lupus Erythematosus, sponsored by Northwell Health.

Completed
Registry status
40
Enrollment target
1
Study location

NCT01230112 is a study of Systemic Lupus Erythematosus that has completed, run by Northwell Health. The registered enrollment target is 40 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01230112, a study of Systemic Lupus Erythematosus, has completed, sponsored by Northwell Health.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Study Locations (1)

New York

  • Feinstein Institute for Medical Research - Manhasset

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2009-12
Est. Completion 2012-04

Sponsor

Northwell Health

370 total trials

What the Registry Record Tells You About NCT01230112

The ClinicalTrials.gov registry entry for NCT01230112 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (89% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.

NCT01230112 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01230112 about?

NCT01230112 is a clinical study titled "The Role of ITGAM in Systemic Lupus Erythematosus". Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

What is the current status of trial NCT01230112?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2009-12. Estimated completion is 2012-04.

What conditions does trial NCT01230112 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

Who is sponsoring clinical trial NCT01230112?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01230112 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.